Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Vinco Ventures

Camber Energy

Which penny stocks are on your watchlist for next month? The post Hot Penny Stocks to Buy This Month?

Hot Penny Stocks to Buy This Month? 3 to Watch Now

Chembio Diagnostics Inc (NASDAQ: CEMI) is trading higher Friday after the company announced its launch of commercial distribution of SCOV-2 Ag Detect Rapid Test, a third party COVID-19 antigen assay. Chembio Diagnostics said product inventory is on-hand and immediately available for shipment to customers across the United States.

Why Chembio Diagnostics Shares Are Trading Higher Today

Chembio Diagnostics Inc (NASDAQ: CEMI) has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test.  Product inventory is on-hand and immediately available for shipment to Chembio customers across the U.S.

Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay

HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States.

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

Implied Volatility Surging for Chembio Diagnostics (CEMI) Stock Options

Chembio Diagnostics Inc's (NASDAQ: CEMI) Q2 sales increased 26% Y/Y to $6.5 million, missing the consensus of $8.5 million. Net product sales increased 4% to $3.9 million.

Chembio Diagnostics Stock Falls As Q2 Earnings Lag Consensus, Doubt On Ability To Continue As Going Concern

The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) fell over 10% pre-market. This is why it happened.

CEMI Stock Price Falls Over 10% Pre-Market: Why It Happened

The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) increased by over 9% pre-market. This is why it happened.

CEMI Stock Price Increases Over 9% Pre-Market: Why It Happened

Lexinfintech Hlds

Sirius XM Holdings Inc

August appears to be a solid time to consider adding stocks. Today we looked at how to screen for highly-ranked stocks trading for under $10 a share.

Find Cheap Stocks Under $10 to Buy in August

AzurRx BioPharma

Xenetic Biosciences

Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.

Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021

Chembio Diagnostics Inc. (NASDAQ:CEMI) shares rallied higher Thursday after the company received a $4 million HIV test purchase order from the Partnership for Supply Chain Management, supported by the Global Fund for shipment in early 2022. Chembio Diagnostics peaked at an intraday high of $6.93, but eventually cratered from that high to close down 19% at $4.31 per share.

Chembio Diagnostics Pops And Drops: A Technical Look

Chembio Diagnostics Inc (NASDAQ: CEMI) has received a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported by The Global Fund. The order comes to purchase Chembio's HIV 1/2 STAT-PAK Assay for shipment to Ethiopia into early 2022.

Chembio To Ship $4M Of WHO-Qualified HIV Test Kits To Ethiopia In 2022

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported by The Global Fund, for the purchase of Chembio's HIV 1/2 STAT-PAK Assay for shipment to Ethiopia into early 2022. Chembio's delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.

Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund

The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) increased by 159.22% yesterday. This is why it happened.

CEMI Stock Increased 159.22%: Why It Happened

Day traders are cheering on Chembio Diagnostic's staggering intraday move after the company announced a purchase order for its COVID-19 antigen tests.

Day traders are cheering on a small medical-diagnostics company that's soared 237% today after announcing a $28 million order

CEMI stock is soaring after inking its first multi-million dollar sales contract for its FDA-approved Covid-19 rapid antigen test. The post CEMI Stock: $28M Covid Test Order Sends Chembio Diagnostics Skyrocketing appeared first on InvestorPlace.

CEMI Stock: $28M Covid Test Order Sends Chembio Diagnostics Skyrocketing

Shares of Chembio Diagnostics Inc. rocketed 102% on heavy volume in premarket trading Wednesday, infectious diseases diagnostic company announced a $28.3 million purchase order its SARS-CoV-2 antigen tests from Brazil-based Bio-Manguinhos. Trading volume spiked to 22.3 million shares, compared with the full-day average of about 525,100 shares.

Chembio's stock more than doubles off 11-year low after large order for COVID-19 antigen tests

Hut 8 Mining Corp

Energy Fuels

Penny stocks to buy according to Wall Street analysts. But are they worth the risk?

Best Penny Stocks To Buy Now? Analysts See 85%-288% Upside In 3

The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) increased by over 100% pre-market. This is why it happened.

CEMI Stock Increases Over 100% Pre-Market: Why It Happened

Chembio Diagnostics Inc (NASDAQ: CEMI) received a $28.3 million purchase order from Brazil's Bio-Manguinhos to purchase Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021.  The Antigen test detects the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in 15-20 minutes using a minimally invasive nasal swab.

Chembio Stock More Than Doubles On $28M Purchase Order For Its COVID Antigen Tests

HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil's Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembio's delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Chembio Diagnostics' (CEMI) CEO Rick Eberly on Q1 2021 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2021. Chembio achieved first quarter 2021 total revenue of $8.7 million and product revenue of $4.0 million, representing growth of 27% and a decline of 30%, respectively, compared to the prior year period.

Chembio Diagnostics Reports First Quarter 2021 Financial Results

HAUPPAUGE, N.Y., April 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2021 after the close of trading on Thursday, May 6, 2021.

News for Chembio Diagnostics Stock (CEMI)